Nad+ and cardiovascular aging: what we know so far

When we think about cardiovascular aging, the image that typically comes to mind is straightforward: rising blood pressure numbers on medical charts, arterial walls becoming stiffer and less flexible, cholesterol plaques accumulating in coronary arteries, and an ever-increasing risk of heart attacks and strokes. These clinical manifestations are real and important, but they represent only the surface layer of a much deeper biological process.

Beneath these visible changes lies a progressive shift in how blood vessels and the heart handle fundamental cellular challenges: energy demand, oxidative stress, inflammation, and damage repair. And increasingly, research suggests that a single molecule sits near the intersection of all these processes: NAD+ (nicotinamide adenine dinucleotide).

NAD+ is essential for mitochondrial energy metabolism, cellular redox balance, and the activity of NAD+-dependent enzymes that regulate stress responses and longevity pathways. As NAD+ levels decline with age—a well-established phenomenon documented across species and tissues—cardiovascular function may deteriorate in ways that extend far beyond what traditional risk factors can explain.

But here's what makes this topic scientifically challenging: while the mechanistic rationale linking NAD+ decline to cardiovascular aging is compelling, and animal studies are highly suggestive, human outcome data are still emerging. This article examines what we actually know, what remains uncertain, and how to think about NAD+ in the context of cardiovascular health with appropriate scientific rigor.

Understanding NAD+ and why it matters for cardiovascular health

NAD+ isn't a trendy supplement ingredient that appeared out of nowhere—it's a fundamental coenzyme that's been essential to cellular metabolism since the earliest forms of life. Every cell in your body, including the billions of cells making up your heart and blood vessels, depends on NAD+ for basic survival and function.

Specifically, NAD+ is required for several processes that are particularly critical in cardiovascular tissues:

• Mitochondrial ATP production: Cardiovascular tissues have extraordinary energy demands. The heart beats roughly 100,000 times per day, and blood vessels must constantly regulate tone and respond to changing demands. This requires massive, continuous energy generation
• Redox reactions: NAD+ participates in oxidation-reduction reactions that maintain cellular stability and manage oxidative stress—a major driver of vascular aging
• Sirtuin activity: NAD+-dependent enzymes like SIRT1 and SIRT3 regulate stress responses, mitochondrial quality control, inflammation, and cellular senescence in vascular cells
• DNA repair processes: PARP enzymes that fix DNA damage consume NAD+ as fuel, and cardiovascular cells experience substantial oxidative DNA damage

In cardiovascular tissues—where energy demand is relentless and oxidative stress is high—NAD+ availability can profoundly influence how cells respond to aging-related stressors. Comprehensive reviews published in Circulation and the American Journal of Physiology - Heart and Circulatory Physiology have documented how NAD+ pools decline with aging and how this decline intersects with cardiovascular risk factors including obesity, hypertension, and metabolic dysfunction.

NAD+ decline and vascular aging: the mechanistic framework

One of the most important concepts in cardiovascular aging is endothelial dysfunction—the progressive impairment of the endothelium, the thin layer of cells lining all blood vessels. When the endothelium functions properly, it regulates vascular tone (how much vessels constrict or dilate), manages inflammation, maintains barrier function, and prevents thrombosis.

With age, endothelial function deteriorates. The clinical manifestations include:

• Reduced nitric oxide bioavailability (nitric oxide is essential for vascular dilation and health)
• Increased oxidative stress and reactive oxygen species production
• Heightened inflammatory signaling
• Progressive arterial stiffness
• Impaired vascular repair mechanisms

A comprehensive review on endothelial NAD+ deficiency and vascular aging, published in the American Journal of Physiology - Cell Physiology, argues that age-related NAD+ decline contributes significantly to endothelial dysfunction through several interconnected mechanisms:

• Impaired sirtuin signaling (particularly SIRT1, which protects endothelial health)
• Increased oxidative stress due to mitochondrial dysfunction
• Altered inflammatory pathways and increased pro-inflammatory cytokine production
• Reduced capacity for vascular repair and regeneration

This mechanistic synthesis doesn't prove that boosting NAD+ reverses vascular aging in humans—we need clinical trials for that—but it provides a biologically coherent framework for understanding why NAD+ might matter for cardiovascular health beyond just "general cellular energy."

The CD38 connection: inflammation meets NAD+ depletion

One of the strongest mechanistic bridges between aging, inflammation, and NAD+ decline in the cardiovascular system involves an enzyme called CD38. This connection has fundamentally changed how researchers think about the intersection of inflammaging and metabolic aging.

CD38 is a major NAD+-consuming enzyme—it literally breaks down NAD+ at a rapid rate. Groundbreaking research published in Cell Metabolism by Camacho-Pereira and colleagues demonstrated several critical findings:

• CD38 expression and activity increase substantially with age in multiple tissues, including vascular tissue
• CD38 is required for age-related NAD+ decline and mitochondrial dysfunction
• The mechanisms involve SIRT3-dependent pathways that are crucial for mitochondrial health
• Genetic deletion or pharmacological inhibition of CD38 in mice preserved NAD+ levels and improved metabolic function

Why does this matter specifically for cardiovascular aging?

• Aging is associated with chronic low-grade inflammation ("inflammaging") throughout the body, including in vascular tissue
• Inflammatory signaling can upregulate CD38 expression in endothelial cells and vascular smooth muscle
• Higher CD38 activity lowers NAD+ availability, which may worsen mitochondrial function and endothelial performance
• This creates a vicious cycle: inflammation drives CD38, CD38 depletes NAD+, NAD+ depletion worsens cellular function, and impaired cellular function generates more inflammation

More recent vascular-focused research has reported CD38 upregulation in human hypertensive aortas, linking endothelial CD38 directly to NAD+ depletion and vascular damage mechanisms in the context of hypertension. These findings combine preclinical animal work with observations in human vascular tissue, strengthening the mechanistic case.

CD38 provides a plausible molecular route by which age-related inflammation translates into NAD+ depletion and vascular dysfunction. However, therapeutic implications in healthy human populations remain under active investigation.

Sirtuins, NAD+, and the endothelium

Sirtuins are a family of NAD+-dependent enzymes that regulate an extraordinary range of cellular processes relevant to aging and cardiovascular health. Because sirtuins literally require NAD+ to function—they consume NAD+ as a substrate—declining NAD+ levels directly impair sirtuin activity.

SIRT1 is particularly crucial for vascular health. Extensive evidence, summarized in comprehensive reviews in Circulation Research and other cardiovascular journals, links SIRT1 deficits with endothelial dysfunction and multiple cardiovascular aging phenotypes:

• Nitric oxide production: SIRT1 regulates eNOS (endothelial nitric oxide synthase), the enzyme responsible for producing the vasodilator nitric oxide
• Oxidative stress management: SIRT1 activates antioxidant enzymes and reduces ROS production
• Inflammatory signaling: SIRT1 suppresses NF-κB, a master regulator of inflammatory pathways
• Cellular senescence: SIRT1 helps prevent endothelial cells from entering senescent states
• Mitochondrial function: SIRT1 coordinates with other sirtuins (particularly SIRT3) to maintain mitochondrial health

When NAD+ availability drops with age, NAD+-dependent sirtuin signaling capacity drops with it. This potentially shifts endothelial cells toward a more pro-oxidative, pro-inflammatory, senescence-prone state—precisely the hallmarks of vascular aging documented extensively across the research literature.

The mechanistic chain is clear: NAD+ decline → impaired sirtuin function → endothelial dysfunction → vascular aging. What requires more research is demonstrating that restoring NAD+ in humans reverses this cascade in clinically meaningful ways.

NAD+ metabolism in the heart: cardiac-specific considerations

The heart presents unique metabolic challenges. It's the most metabolically active organ relative to its size, contracting continuously, 24/7, throughout an entire lifetime. This extraordinary energy demand makes cardiac tissue especially sensitive to anything affecting mitochondrial function—including NAD+ availability.

Comprehensive reviews in Circulation detail how NAD+ pools are involved in:

• Cardiac metabolism: The heart's ability to switch between different fuel sources (glucose, fatty acids, ketones) depends on NAD+-dependent pathways
• Stress tolerance: Cardiac response to ischemia, hypertension, or metabolic stress involves NAD+-dependent protective mechanisms
• Disease pathways: Heart failure, cardiomyopathy, and other cardiac diseases show altered NAD+ metabolism

The evidence suggests that NAD+ levels decline in both normal aging and major cardiovascular disease states. Mechanistically, reduced cardiac NAD+ may worsen:

• Mitochondrial efficiency and energy production capacity
• Redox balance and oxidative stress handling
• Repair signaling during chronic metabolic stress
• Resistance to ischemic injury

However—and this is crucial for scientific integrity—the leap from "NAD+ is important for cardiac function" to "NAD+ boosting prevents heart disease in humans" requires rigorous human clinical trials with cardiovascular outcomes. We're not fully there yet.

What human clinical trials actually show (and what they don't)

This is where scientific rigor becomes most important. When evaluating NAD+ and cardiovascular health, we need to distinguish carefully between mechanistic plausibility, animal data, and actual human clinical evidence.

1. NAD+ can be raised in humans with NAD+ precursors

A randomized, double-blind, placebo-controlled crossover trial published in Nature Communications by Martens and colleagues established that nicotinamide riboside (NR) supplementation is well-tolerated and increases NAD+ metabolism in healthy middle-aged and older adults.

This establishes a fundamental proof of concept: oral NAD+ precursors can raise NAD+-related measures in humans. This isn't trivial—it confirms that the intervention is biologically active and reaches its intended target.

2. Vascular endpoints: early signals, not definitive answers

Several trials have specifically examined vascular endpoints with NAD+ precursor supplementation:

A trial protocol published in Contemporary Clinical Trials focuses specifically on whether NR can reduce systolic blood pressure and aortic stiffness in midlife and older adults with elevated systolic BP. The study design indicates that vascular endpoints like blood pressure and pulse wave velocity (a measure of arterial stiffness) are testable, clinically relevant targets for NAD+ restoration.

A 2024 randomized, double-blind trial in people with peripheral artery disease evaluated NR (with or without resveratrol) and reported improvement in 6-minute walk distance compared with placebo at 6 months. This represents a functional endpoint relevant to vascular disease, though it's specific to a diseased population rather than general vascular aging prevention.

These results are encouraging and mechanistically consistent, but they're preliminary signals rather than definitive proof of cardiovascular protection.

3. What's still missing from the human evidence base

Scientific honesty requires acknowledging significant evidence gaps:

• Large, long-duration trials showing that NAD+ precursors reduce heart attacks, strokes, or cardiovascular mortality
• Consistent evidence that NAD+ restoration meaningfully reduces arterial stiffness across diverse, healthy populations
• Definitive human evidence that NAD+ precursors reverse endothelial dysfunction in routine clinical practice
• Head-to-head comparisons with established cardiovascular interventions
• Long-term safety data in cardiovascular patient populations

The most scientifically defensible summary is: Human trials support that NAD+ precursors can increase NAD+ metabolism, with emerging but not definitive signals for cardiovascular functional benefits in specific contexts. The overall clinical impact on cardiovascular aging outcomes is still being defined.

What we can say with scientific confidence

Based on the current mechanistic and clinical literature, several statements can be made with reasonable confidence:

Strongly supported by evidence:

• NAD+ is central to mitochondrial function, redox balance, and NAD+-dependent enzymes that are critical for vascular and cardiac biology
• NAD+ levels decline with age in cardiovascular tissues across multiple species
• Age-related inflammation increases NAD+ consumption via CD38, which is strongly implicated in NAD+ decline
• Endothelial dysfunction and vascular aging mechanistically intersect with NAD+ decline and altered sirtuin signaling
• In humans, NAD+ precursors (particularly NR in published RCTs) can raise NAD+ metabolism with good tolerability

Plausible but requiring more evidence:

• NAD+ restoration produces meaningful improvements in vascular function across diverse populations
• NAD+ precursors reduce cardiovascular disease incidence or mortality in long-term trials
• The magnitude of benefit from NAD+ support is clinically significant compared to established interventions

Not yet proven:

• NAD+ supplementation alone reverses established cardiovascular disease
• NAD+ precursors provide cardiovascular protection equivalent to or superior to lifestyle interventions
• Long-term NAD+ restoration is safe and effective across all cardiovascular patient populations

Practical implications: cardiovascular health foundations remain essential

Even as NAD+ biology becomes increasingly understood, it's crucial to maintain perspective on what has the strongest evidence base for cardiovascular health. The interventions with the most robust, long-term, multi-trial evidence for reducing cardiovascular risk remain:

Established cardiovascular interventions:

• Blood pressure control: Arguably the single most important modifiable cardiovascular risk factor
• Insulin sensitivity and metabolic health: Preventing or managing metabolic syndrome and diabetes
• Regular exercise: Both aerobic and resistance training have overwhelming evidence for cardiovascular benefit
• Sleep quality and circadian regularity: Poor sleep is an independent cardiovascular risk factor
• Smoking avoidance: Still one of the strongest modifiable risk factors
• Lipid management: When indicated based on individual risk assessment
• Body composition optimization: Particularly reduction of visceral adipose tissue

NAD+ support through precursor supplementation may represent an additional layer of metabolic optimization for some individuals, particularly those focused on longevity and healthy aging. But it should complement, not replace, these established foundations of cardiovascular health.

Think of it this way: no amount of NAD+ supplementation will compensate for uncontrolled hypertension, poor metabolic health, or sedentary lifestyle. The proven interventions remain the foundation; NAD+ support is potentially a refinement or addition for those already optimizing the basics.

Future directions: what research is needed

To move from mechanistic plausibility to clinical validation, the field needs:

• Long-term cardiovascular outcome trials: Studies measuring actual cardiovascular events (heart attack, stroke, heart failure) rather than just biomarkers
• Diverse population studies: Including different age groups, ethnicities, and baseline cardiovascular risk profiles
• Dose-response studies: Establishing optimal dosing for cardiovascular endpoints
• Mechanistic biomarker validation: Confirming that NAD+ elevation in blood corresponds to tissue-level changes in heart and vessels
• Comparative effectiveness research: How do NAD+ precursors compare to established interventions?
• Long-term safety data: Particularly in cardiovascular patient populations taking multiple medications

Some of these studies are likely underway. As results emerge over the coming years, our understanding of NAD+'s role in cardiovascular aging will become clearer and more actionable.

Final thoughts: mechanism and evidence

The intersection of NAD+ biology and cardiovascular aging represents a fascinating example of how fundamental cellular metabolism connects to organ-level function and disease risk. The mechanistic framework is scientifically coherent and well-supported by preclinical research:

• NAD+ is essential for cardiovascular tissue function
• NAD+ declines with age in ways that appear biologically relevant
• CD38-mediated NAD+ depletion provides a link between inflammation and metabolic dysfunction
• Impaired sirtuin signaling connects NAD+ decline to endothelial aging
• Restoring NAD+ improves vascular and cardiac function in animal models

The human evidence is encouraging but incomplete. NAD+ precursors can raise NAD+ levels in humans, and early signals suggest potential cardiovascular benefits in specific contexts. What we don't yet have is definitive, long-term proof that NAD+ restoration meaningfully reduces cardiovascular disease burden across general populations.

This isn't cause for dismissing NAD+ as irrelevant to cardiovascular health—the mechanistic case is too strong for that. But it is reason for maintaining scientific rigor about what's proven versus what's promising, and for ensuring that focus on emerging interventions doesn't distract from established, evidence-based cardiovascular health practices.

For individuals interested in longevity and cardiovascular optimization, a rational approach involves: (1) optimizing the proven foundations of cardiovascular health, (2) staying informed about emerging NAD+ research, and (3) potentially considering NAD+ support as part of a comprehensive strategy, while maintaining realistic expectations about current evidence limitations.

As research continues, our understanding will evolve. The mechanistic insights we already have are valuable; the clinical translation is still developing. That's not a weakness of the science—it's simply where we are in the research timeline.

References

1. Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism, 27(3), 529-547. https://doi.org/10.1016/j.cmet.2018.02.011
2. Kiss, T., Giles, C. B., Tarantini, S., Yabluchanskiy, A., Balasubramanian, P., Gautam, T., ... & Ungvari, Z. (2019). Nicotinamide mononucleotide (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and anti-atherogenic effects. GeroScience, 41(4), 419-439. https://doi.org/10.1007/s11357-019-00095-x
3. Camacho-Pereira, J., Tarragó, M. G., Chini, C. C., Nin, V., Escande, C., Warner, G. M., ... & Chini, E. N. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006
4. Das, A., Huang, G. X., Bonkowski, M. S., Longchamp, A., Li, C., Schultz, M. B., ... & Sinclair, D. A. (2018). Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging. Cell, 173(1), 74-89. https://doi.org/10.1016/j.cell.2018.02.008
5. Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., ... & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286. https://doi.org/10.1038/s41467-018-03421-7
6. Seals, D. R., Kaplon, R. E., Gioscia-Ryan, R. A., & LaRocca, T. J. (2014). You're only as old as your arteries: translational strategies for preserving vascular endothelial function with aging. Physiology, 29(4), 250-264. https://doi.org/10.1152/physiol.00059.2013
7. Kaye, D. M., Shihata, W. A., Jama, H. A., Tsyganov, K., Ziemann, M., Kiriazis, H., ... & Marques, F. Z. (2020). Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease. Circulation, 141(17), 1393-1403. https://doi.org/10.1161/CIRCULATIONAHA.119.043081